Gadot Yifat, Koren Gideon
The Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics, Hospital for Sick Children, Toronto ON.
J Obstet Gynaecol Can. 2015 Jan;37(1):56-63. doi: 10.1016/S1701-2163(15)30364-9.
Studies have consistently reported a decrease in the use of antidepressants during pregnancy compared with the pre-pregnancy period. Multiple recent studies have focused on the potential fetal risks of selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), with very little attention paid to maternal risks. The maternal risks of these medications are the focus of this review. Untreated depression is associated with increased risks of maternal morbidity, both somatic and psychiatric. In contrast, use of antidepressants has been associated with increased risks of hypertension, preeclampsia, and bleeding. In this review we present the evidence for maternal risks in an attempt to develop a risk-benefit ratio.
研究一致报告称，与怀孕前相比，孕期抗抑郁药的使用有所减少。最近多项研究聚焦于选择性5-羟色胺再摄取抑制剂（SSRI）和选择性去甲肾上腺素再摄取抑制剂（SNRI）对胎儿的潜在风险，而对母亲风险关注甚少。这些药物对母亲的风险是本综述的重点。未经治疗的抑郁症与母亲躯体和精神疾病发病率增加有关。相比之下，使用抗抑郁药与高血压、先兆子痫和出血风险增加有关。在本综述中，我们展示了母亲风险的证据，试图得出风险效益比。
